Read every relevant label field
Request the exact preparation, dispensing pharmacy and written instructions rather than rely on a category label.
Compare the named ingredients, the full formulation where disclosed and the stated amounts. A headline active, blend total and complete ingredient list answer different questions. Where information is missing, ask for it rather than infer it from another product. Keep other products already used in view so the comparison can identify an added ingredient or role. More actives and a higher displayed number do not establish a better finished-product result. Read the related care guide for the wider context.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
1. CoreAge Rx: compare the actual care and medicine
CoreAge publishes compounded semaglutide at $79 per month on a 12-month plan and says there is no membership fee. That gives a straightforward reference beside services with separate care charges. The useful budget question is what supply and follow-up the selected prescription includes, and whether the quoted rate remains the same at renewal. Its $129/month on a 12-month plan tirzepatide offer belongs in a different medicine comparison. Read CoreAge Rx review and the actual semaglutide product page before treating the displayed monthly figure as a personalized prescription quote.
Request any formula information absent from the public panel. The disclosed headline ingredient is useful, but cannot answer every question about a finished preparation or individual suitability. The CoreAge Rx review records the purchase model and remaining questions.
CoreAge Rx’s updated starting prices are $79/month equivalent for semaglutide and $129/month for tirzepatide on 12-month plans ($948 and $1,548 total). One-month plans cost $139 and $199. No separate membership fee is advertised. These figures describe selected supply periods, not every product or a completed order; confirm the exact prescription and invoice.
Read CoreAge Rx as a finished preparation with its own ingredients and directions. The purchase reference is Semaglutide from $79/month; tirzepatide from $129/month, both on 12-month plans, but label completeness is a separate question from that figure. Distinguish a named active, a blend total and a complete disclosed formulation. A missing amount should remain open rather than be inferred from another product’s panel or ingredient research.
Sources: Semaglutide - CoreAge Rx · Tirzepatide - CoreAge Rx · CoreAge Rx - Your Health On Your Time · CoreAge Rx — Refund, Return, Subscription & Shipping Policy - CoreAge Rx · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · Prescription Medications to Treat Overweight & Obesity - NIDDK
2. SuperHealthy Rx — GLP-1 care
SuperHealthy Rx advertises compounded semaglutide from $85/month and tirzepatide from $135/month. The linked offer says the provider visit and shipping are included. Confirm the amount due, plan term and refill settings; a prescription depends on clinician review. These are published service terms, not independently tested outcomes. [Current offer](https://try.superhealthyrx.com/superhealthy-v1?utm_source=top5glp1.com&utm_medium=referral&utm_campaign=provider_comparison).
Sources:
3. Likeness Rx — GLP-1 weight care
A clear buying decision starts with the selected supply period. Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.
The lowest monthly equivalents accompany 12-month subscriptions: $948 for semaglutide or $1,548 for tirzepatide. One-month plans are $139 and $199. The page says the selected term renews automatically; check the amount due and cancellation date.
The public site describes licensed-provider review, shipping after approval and care-team messaging. Those are service statements rather than measured response times.
These are provider-published terms checked October 4, 2026. Prescription approval is conditional. Compounded medications are not FDA-approved; we have not tested the treatment, pharmacy fulfillment or patient outcomes.
Product and subscription information checked at likenessrx.com on October 4, 2026.
Sources: Likeness Rx — GLP-1 weight care
4. Ro: compare the actual care and medicine
Ro lists an ongoing $149 month-to-month membership after a $39 first month, with medication extra. Its $74 monthly equivalent is attached to a twelve-month prepaid membership; intermediate prepaid terms have different equivalents. Those longer terms may lower the displayed average while requiring a larger upfront care payment. Ro review helps compare the membership and medicine separately. A person choosing monthly flexibility should calculate with the actual $149 membership and selected medication bill, then ask which enrollment and pharmacy charges can be refunded.
Read the complete label alongside the other products already used. Identify any duplicated active or supporting ingredient before deciding whether this option fills a different role. The Ro review records the purchase model and remaining questions.
The current page gives oral medicines their own place rather than treating every GLP-1 offer as a shot. An oral option still requires a prescribing decision and does not become appropriate merely because swallowing a pill seems easier. The page’s brand listings also differ from a compounded-liquid oral offer on another platform; formulation and approval status should be compared directly.
For Ro, connect each disclosed field to the decision it can actually support. Ingredient identity can establish what is present; a stated amount can support a narrower comparison. Neither automatically predicts the response to the finished product. Keep the published order reference, Membership $39 first month, then $149/month monthly or $74/month equivalent on annual prepayment; medicine extra, beside the full formula and the unresolved details before deciding whether the purchase fills a defined role.
Sources: Weight Loss Program Pricing | Ro · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · Prescription Medications to Treat Overweight & Obesity - NIDDK
5. Mochi Health: compare the actual care and medicine
Mochi shows compounded semaglutide medication cards from $60, alongside a separate $79 monthly membership. A new-member membership promotion is $39 for the first month, with medication and diagnostic services excluded from that membership charge. Combining the displayed standard membership and minimum medication card produces an illustrative $139 before any separate diagnostics, if that medication figure applies to the selected order. It is not a universal quote or a price promise. Mochi Health review explains why the smallest medication card should not be compared directly with a prescription-inclusive plan.
Disclosed amounts can support a careful comparison; a missing amount should remain missing. A percentage or blend weight does not establish equivalence to another molecule or complete product. The Mochi Health review records the purchase model and remaining questions.
The current page shows compounded semaglutide from $60, tirzepatide from $90 and a semaglutide pill from $62, alongside other oral choices. These are medication-card starting figures. The opening material reviewed does not establish a complete, universal membership-plus-medicine total. Comparing one of those figures with another company’s bundled program price would mix different units of purchase.
The most useful additional record for Mochi Health is its complete current panel, not only the ingredient highlighted in advertising. Its order reference is Membership $39 introductory month where available, then $79/month; medication cards from $60 semaglutide/$90 tirzepatide extra. Match the exact variant and ask for any missing amount relevant to the comparison. Then place the formula beside existing products so an additional active or repeated ingredient remains visible.
Sources: Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi Health · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · Prescription Medications to Treat Overweight & Obesity - NIDDK
6. Noom Med: compare the actual care and medicine
Noom’s price page shows a GLP-1Rx program at $129 to start and $249 per month after the first four-week supply, billed quarterly. It separately lists branded-medication telehealth at $39 to start and $129 monthly after month one, also billed quarterly, with medication excluded. That second care-only figure is not an alternative $129 complete prescription plan. Read Noom Med review for the program distinctions. Someone paying cash needs the named plan and medication inclusion in writing before comparing Noom with a medicine-inclusive service.
Keep the product category and full ingredients together. A similar marketing goal does not establish the same formula, clinical purpose or evidence for the finished preparation. The Noom Med review records the purchase model and remaining questions.
The GLP-1Rx program lists $129 to start and $249 per month after the initial four-week supply, billed quarterly. Plus lists $149 to start and $299 per month afterward, also quarterly. Microdose lists $49 to start and $179 per month afterward. Those figures should not be reduced to a single Noom price; the later bill and program selection matter more than the cheapest opening headline.
Read Noom Med as a finished preparation with its own ingredients and directions. The purchase reference is GLP-1Rx $129 start, then $249/month billed quarterly, but label completeness is a separate question from that figure. Distinguish a named active, a blend total and a complete disclosed formulation. A missing amount should remain open rather than be inferred from another product’s panel or ingredient research.
Sources: Noom Med - GLP-1 Medications for Weight Loss · Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · Prescription Medications to Treat Overweight & Obesity - NIDDK
7. RemedyMeds: compare the actual care and medicine
RemedyMeds advertises compounded semaglutide and tirzepatide through an online care pathway. Its page emphasizes month-to-month participation and also promotes a microdose program. The precise selected preparation matters more than the broad GLP-1 label on the homepage.
Use this alternative to clarify what changes in the routine, rather than count ingredients as a quality score. Ask for current instructions and any unresolved label information. The RemedyMeds review records the purchase model and remaining questions.
RemedyMeds places a microdose offer beside its semaglutide and tirzepatide descriptions. The reviewed opening does not establish the exact ingredient for every microdose enrollment. A program name should not be used to infer a medicine, amount or suitability. The relevant clinical question is which preparation would actually be prescribed and why that choice meets the person’s needs.
For RemedyMeds, connect each disclosed field to the decision it can actually support. Ingredient identity can establish what is present; a stated amount can support a narrower comparison. Neither automatically predicts the response to the finished product. Keep the published order reference, Exact recurring price not established in the reviewed opening, beside the full formula and the unresolved details before deciding whether the purchase fills a defined role.
Sources: RemedyMeds · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · Prescription Medications to Treat Overweight & Obesity - NIDDK
Compare the care model after identifying the actual medicine
A GLP-1 program can combine medical assessment, a prescription, pharmacy fulfillment, coaching and administrative support. Different providers bundle these differently. Start by identifying what is included in the care payment and which medicine cost is separate. NIDDK describes prescription weight-management medicines as part of care that considers benefits, side effects, health history and other medicines. A branded-access program and a direct compounded offer should remain distinct in that conversation.
Semaglutide and tirzepatide are ingredient names, rather than a complete description of every product sold under them. Manufacturer-branded medicines have their own approved labels; compounded preparations are not FDA-approved finished products. The pharmacy, preparation and final instructions therefore belong beside the price. FDA has described concerns with unapproved GLP-1 products, including dosing and sourcing issues. A useful comparison identifies the exact order and continuing clinical contact before treating a broad category name as enough information.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Read a formula as a set of specific fields
Begin with the ingredient being compared, then read its stated amount, the rest of the formula and the full labeled serving or application. A blend total and a single-ingredient concentration are different disclosures. For example, a hypothetical 500 mg blend of four ingredients does not establish that each contributes 125 mg. Likewise, a large scoop or prominent percentage cannot identify every component of the finished formula. Keep the stated field and the unresolved field separate.
Next place the new panel beside the products already used. That can reveal an overlapping active, a repeated nutrient or an additional botanical that was not apparent from the product name. For personalized treatment, use the final prescribed panel rather than a list of possible ingredients from the intake page. For a fixed retail item, match the exact flavor, size and variant. The point is an understandable formula with a defined role, rather than an ingredient count used as a substitute for evidence.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Clinical eligibility and the payment decision are separate steps
NIDDK describes weight-management prescribing as an individual decision that considers potential benefits, possible side effects, current health, other medicines and family history. For adults, its general discussion includes BMI of 30 or greater, or 27 or greater with weight-related health problems. Those are starting clinical considerations rather than an eligibility test supplied by this page. The clinician assesses the actual product and circumstances; a sales offer or membership payment cannot establish the prescription.
Discuss reproductive plans and other relevant changes before enrollment and during care. NIDDK advises against weight-loss medication during pregnancy or when planning pregnancy. Confirm the selected product’s own information with the clinician rather than transfer advice from another preparation. Once the care decision is made, obtain the complete medicine and service invoice, the ordinary renewal and the process for a clinically necessary change. That keeps treatment assessment and financial commitment understandable without making either one substitute for the other.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Is a care membership the same thing as a medication-inclusive plan?
No. A membership can cover assessment, visits, coaching or insurance assistance while a pharmacy charges separately for medication. A direct offer may bundle some of those costs. Ask for the selected plan’s complete invoice and exact product, including delivery and ordinary renewal. Compare what each payment actually buys rather than place an introductory service fee in the medicine column.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Are branded medicines and compounds the same finished products?
They should remain distinct. Manufacturer-branded medicines have their own approved labels, while compounded preparations are not FDA-approved finished products. The pharmacy, concentration, ingredients and directions must be identified for the actual prescription. Trials of a branded product do not establish the results of an unspecified compound. A program comparison should make those identities clear rather than assume equivalence from an ingredient name.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
What should happen if the prescription changes after assessment?
Ask the provider how the change affects medication supply, care fees and any advance payment. Those terms belong in the selected agreement and may differ between a membership and a prescription-inclusive purchase. Keep the prescribing contact available for clinical questions and customer support available for the order. A paid renewal or shipment notice is not, by itself, confirmation that the same treatment remains appropriate.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Prepare a complete comparison before enrollment
Put the answers beside the actual label and selected order. Keep any unresolved formula, supply or renewal question visible before deciding whether this option fits the routine.
For the audience-focused care questions, read Best GLP-1 programs for women: five medicine and care models and Best GLP-1 programs for men: five care and cost comparisons.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Official sources
Public-page information checked October 1, 2026. Prices, availability and terms can change. We did not perform patient care or checkout.
- Semaglutide - CoreAge Rx ↗Checked 2026-10-01 · official public source
- Tirzepatide - CoreAge Rx ↗Checked 2026-10-01 · official public source
- Weight Loss Program Pricing | Ro ↗Checked 2026-10-01 · official public source
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗Checked 2026-10-01 · official public source
- Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi Health ↗Checked 2026-10-01 · official public source
- Noom Med - GLP-1 Medications for Weight Loss ↗Checked 2026-10-01 · official public source
- Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs ↗Checked 2026-10-01 · official public source
- RemedyMeds ↗Checked 2026-10-01 · official public source
- Prescription Medications to Treat Overweight & Obesity - NIDDK ↗Checked 2026-10-01 · official public source
- CoreAge Rx - Your Health On Your Time ↗Checked 2026-10-01 · official public source
- CoreAge Rx — Refund, Return, Subscription & Shipping Policy - CoreAge Rx ↗Checked 2026-10-01 · official public source